J Infect Dis: 糖尿病和糖尿病前期对抗结核治疗结果的影响

2021-10-25 MedSci原创 MedSci原创

糖尿病 (DM) 已经被世界卫生组织 (WHO) 认可为全球性流行疾病,这种代谢性疾病使活动性结核病 (TB) 的的发生风险增加了三倍。

      糖尿病 (DM) 已经被世界卫生组织 (WHO) 认可为全球性流行疾病,这种代谢性疾病使活动性结核病 (TB) 的的发生风险增加了三倍。糖尿病患者血糖控制不佳的时候容易并发多种疾病,而结核是最容易和糖尿病一起发生的一种传染病。有文献报道,糖尿病患者结核感染率是正常人的5-6倍,所以糖尿病患者中结核病还是比较多见的,2019年,全世界约有 400,000 名结核病患者 (PWTB) 被诊断出患有糖尿病。目前尚不清楚糖尿病或糖尿病前期是否会影响结核病患者 (PWTB) 的治疗结果或是会导致死亡风险的增加,因此,本项研究旨在对两者的关系进行进一步分析。

 

      研究人员对2015年至2019年期间参加巴西结核病区域前瞻性观察研究 (RePORT) 的经培养确认的PWTB(n = 643)患者进行了回顾性分析,根据患者基线糖化血红蛋白的血糖状态进行疾病严重程度分层。不利的结核病结果定义为治疗失败或病情恶化、复发或死亡;有利的结果是治愈,Logistic 回归模型评估血糖状态和结果之间的关联。

 

      研究结果显示在这两个队列中,抗TB不良结果与吸烟、非法药物使用和 HIV 感染相关。在巴西结核病例中糖尿病,但不是前驱糖尿病,与不利结果相关(调整后相对风险 [aRR]:2.45,p<0.001),此外,在 RePORT-Brazil队列和 SINAN队列中,糖尿病与高死亡风险(结核病治疗期间)相关 (aRR:2.16, p=0.040) 。

 

      在巴西的肺结核病例中,糖尿病与不良结局和死亡率的风险增加有关。因此,这提醒我们在临床工作中需要采取干预措施来改善糖尿病患者的代谢状态从而改善结核病治疗结果。

 

 

原始出处:

María B Arriaga. Et al. The Effect of Diabetes and Prediabetes on Anti-tuberculosis Treatment Outcomes: A Multi-center Prospective Cohort Study.The Journal of Infectious Diseases.2021.

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2013740, encodeId=3fd52013e40b1, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Apr 14 21:56:01 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069538, encodeId=9d3610695385c, content=已拜读,受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Fri Nov 12 10:37:32 CST 2021, time=2021-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254414, encodeId=64b812544145e, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Tue Oct 26 04:56:01 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509915, encodeId=3589150991549, content=<a href='/topic/show?id=d9d855612c2' target=_blank style='color:#2F92EE;'>#抗结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55612, encryptionId=d9d855612c2, topicName=抗结核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c49410165177, createdName=wgx309, createdTime=Tue Oct 26 04:56:01 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535953, encodeId=8295153595314, content=<a href='/topic/show?id=ae716469300' target=_blank style='color:#2F92EE;'>#治疗结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64693, encryptionId=ae716469300, topicName=治疗结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa8e12645559, createdName=jiadan198786, createdTime=Tue Oct 26 04:56:01 CST 2021, time=2021-10-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2013740, encodeId=3fd52013e40b1, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Apr 14 21:56:01 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069538, encodeId=9d3610695385c, content=已拜读,受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Fri Nov 12 10:37:32 CST 2021, time=2021-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254414, encodeId=64b812544145e, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Tue Oct 26 04:56:01 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509915, encodeId=3589150991549, content=<a href='/topic/show?id=d9d855612c2' target=_blank style='color:#2F92EE;'>#抗结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55612, encryptionId=d9d855612c2, topicName=抗结核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c49410165177, createdName=wgx309, createdTime=Tue Oct 26 04:56:01 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535953, encodeId=8295153595314, content=<a href='/topic/show?id=ae716469300' target=_blank style='color:#2F92EE;'>#治疗结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64693, encryptionId=ae716469300, topicName=治疗结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa8e12645559, createdName=jiadan198786, createdTime=Tue Oct 26 04:56:01 CST 2021, time=2021-10-26, status=1, ipAttribution=)]
    2021-11-12 湘雅科教

    已拜读,受益匪浅。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2013740, encodeId=3fd52013e40b1, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Apr 14 21:56:01 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069538, encodeId=9d3610695385c, content=已拜读,受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Fri Nov 12 10:37:32 CST 2021, time=2021-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254414, encodeId=64b812544145e, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Tue Oct 26 04:56:01 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509915, encodeId=3589150991549, content=<a href='/topic/show?id=d9d855612c2' target=_blank style='color:#2F92EE;'>#抗结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55612, encryptionId=d9d855612c2, topicName=抗结核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c49410165177, createdName=wgx309, createdTime=Tue Oct 26 04:56:01 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535953, encodeId=8295153595314, content=<a href='/topic/show?id=ae716469300' target=_blank style='color:#2F92EE;'>#治疗结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64693, encryptionId=ae716469300, topicName=治疗结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa8e12645559, createdName=jiadan198786, createdTime=Tue Oct 26 04:56:01 CST 2021, time=2021-10-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2013740, encodeId=3fd52013e40b1, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Apr 14 21:56:01 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069538, encodeId=9d3610695385c, content=已拜读,受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Fri Nov 12 10:37:32 CST 2021, time=2021-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254414, encodeId=64b812544145e, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Tue Oct 26 04:56:01 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509915, encodeId=3589150991549, content=<a href='/topic/show?id=d9d855612c2' target=_blank style='color:#2F92EE;'>#抗结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55612, encryptionId=d9d855612c2, topicName=抗结核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c49410165177, createdName=wgx309, createdTime=Tue Oct 26 04:56:01 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535953, encodeId=8295153595314, content=<a href='/topic/show?id=ae716469300' target=_blank style='color:#2F92EE;'>#治疗结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64693, encryptionId=ae716469300, topicName=治疗结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa8e12645559, createdName=jiadan198786, createdTime=Tue Oct 26 04:56:01 CST 2021, time=2021-10-26, status=1, ipAttribution=)]
    2021-10-26 wgx309
  5. [GetPortalCommentsPageByObjectIdResponse(id=2013740, encodeId=3fd52013e40b1, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Thu Apr 14 21:56:01 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069538, encodeId=9d3610695385c, content=已拜读,受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6c905475903, createdName=湘雅科教, createdTime=Fri Nov 12 10:37:32 CST 2021, time=2021-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254414, encodeId=64b812544145e, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Tue Oct 26 04:56:01 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509915, encodeId=3589150991549, content=<a href='/topic/show?id=d9d855612c2' target=_blank style='color:#2F92EE;'>#抗结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55612, encryptionId=d9d855612c2, topicName=抗结核)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c49410165177, createdName=wgx309, createdTime=Tue Oct 26 04:56:01 CST 2021, time=2021-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535953, encodeId=8295153595314, content=<a href='/topic/show?id=ae716469300' target=_blank style='color:#2F92EE;'>#治疗结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64693, encryptionId=ae716469300, topicName=治疗结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fa8e12645559, createdName=jiadan198786, createdTime=Tue Oct 26 04:56:01 CST 2021, time=2021-10-26, status=1, ipAttribution=)]

相关资讯

Alzheimer&Dementia:控血糖、稳糖化,糖尿病可以导致痴呆风险加倍!

以血糖控制不佳或心血管并发症为特征的糖尿病与认知障碍的发生和发展的风险更大有关,炎症可能在这些关系中起作用。

Clin Appl Thromb Hemost:一项Meta分析:他汀类药物治疗对2型糖尿病患者糖尿病视网膜病变的影响

近年来,糖尿病(DM)在世界范围内发病率较高。最常见的是2型糖尿病(T2DM),好发于成人。T2DM患者发生微血管和大血管并发症的风险较高。T2DM的血管并发症一直广受关注。大血管并发症主要包括脑血管

Mayo Clin Proc:富含血小板血浆对慢性伤口愈合的疗效和安全性

慢性伤口是常见的慢性病之一,对老龄人口的影响很大,为患者接社会带来较大的经济负担。最常见的与伤口形成有关的疾病包括糖尿病和压力性损伤。目前的治疗方法主要是治疗潜在的疾病和做好伤口护理,以促进健康的肉芽

世界首例:干细胞成功治疗糖尿病患者,让其重新产生胰岛素

1922年,班廷等人发现并提纯了胰岛素,将其成功应用于糖尿病的治疗,这一发现拯救了千千万万的糖尿病患者,尤其是1型糖尿病患者。

母乳喂养好!密集哺乳更好!可通过改善脂质代谢降低GDM女性T2DM风险!

SWIFT研究:近期有妊娠糖尿病的妇女密集哺乳可显著改变产后早期循环脂质谱